Interactions of polymorphic killer Ig-like receptor (KIR) receptors with KIR ligands have been shown to modify the outcome of hematopoietic SCT (HSCT). The association of these genetic factors with different transplantation endpoints, however, varies substantially, depending on clinical and study setup variables. We aimed to assess whether KIR ligands, KIR genes and KIR haplotypes are associated with HSCT outcome of 124 patients with various hematological malignancies, transplanted with 12/ 12 HLA matched grafts from unrelated donors. For this purpose, patient and donor KIR gene and KIR ligand polymorphisms were determined and correlated with clinical data in simple and multiple models. We found that a missing HLA-C2 ligand for donor inhibitory KIR2DL1 was significantly associated with an increased risk of acute GVHD (aGVHD) (II-IV) (hazard ratio (HR) ¼ 2.23, 95% confidence interval (95% CI): 1.21-4.10, P ¼ 0.010), as were the AA KIR haplotypes in patients and donors in HLA-C1CX (HR ¼ 2.37, 95% CI: 1.16-4.84, P ¼ 0.018) and in HLA-Bw4 À (HR ¼ 3.20, 95% CI: 1.35-7.60, P ¼ 0.008) patients. On the contrary, transplantation of HLA-C1C2 patients with KIR2DS2 positive grafts were associated with a decreased risk of aGVHD (II-IV) (HR ¼ 0.24, 95% CI: 0.07-0.85, P ¼ 0.027). Thus, our single center study provides evidence for the modification of aGVHD risk by KIRs and their ligands.
Introduction
The killer Ig-like receptor (KIR) family includes 16 genes coding for inhibitory (L) and activatory (S) receptors expressed on natural killer cells (NK) and subpopulations of gd and ab T cells. 1 The genomic diversity in the KIR region is attributed to the variability in both gene numbers and allelic polymorphism. Population studies revealed more than 100 different KIR genotypes, [2] [3] [4] [5] whereas in family studies over 30 distinct KIR haplotypes were identified. 6 KIR haplotypes fall into two broad categories: group A haplotypes have a restricted gene content of 2DL1, 2DL3, 2DL4, 3DL1, 3DL2, 3DL3, 2DS4, 2DP1 and 3DP1 genes, whereas group B haplotypes may contain other inhibitory and activatory KIR genes.
Some inhibitory KIR receptors interact with HLA class I ligands. Inhibitory receptor KIR2DL1 interacts with HLACw group 2, and KIR2DL2/2DL3 with HLA-Cw group 1 epitopes defined by the amino-acid lysine and asparagine at position 80, respectively. KIR3DL1 specifically recognizes the HLA-Bw4 and KIR3DL2 HLA-A3/A11 epitopes. The strength of these interactions varies, with HLA-C2/KIR2DL1 being the strongest, followed by HLA-C1/KIR2DL2, HLA-C1/KIR2DL3 and HLA-Bw4/ KIR3DL1. 7 Recognition of self-HLA ligands by inhibitory KIR receptors ensures unresponsiveness of NK cells. Inability of NK cells to recognize self-HLA class I leads to increased cytokine production or cytotoxicity. 8 The role of NK cells in the treatment of hematological malignancies is subject to discussion. Ruggeri et al., 9 described clinically beneficial NK cell alloreactivity in HLA-haploidentical hematopoietic SCT (HSCT) where donors' inhibitory NK cell receptors were not engaged by recipients' ligands. This 'missing ligand' effect proved beneficial for AML patients even after HLA matched transplantation, 10 and after autologous transplantation for treatment of solid tumors and lymphomas, 11 but different outcomes have also been reported (reviewed by Witt and Christiansen 12 ). Concordant with the 'missing ligand' model, decreased survival of HLA-C2C2 CML patients was attributed to the delayed reconstitution of inhibitory KIR2DL1 receptors on NK cells post transplant, and hence their inability to kill cells with downregulated HLA-C2C2 ligands in a timely manner. 13 Also, the analyses of the activating KIR receptors showed donors' KIR2DS2 to be a significant risk factor for overall survival (OS) of myeloid leukemia HLA-C2C2 patients. 14 In addition, not only individual genes but also KIR haplotypes of donors were associated with an increased risk of acute GVHD (aGVHD), higher relapse rates and worse OS of HLA-C1C1 patients diagnosed with myeloid diseases. 15 However, all described observations apply to distinct patient groups, and differ substantially depending on transplant protocols, as reviewed recently by Verheyden and Demanet. 16 The purpose of this study was to analyze the association of patient and donor KIR ligands, KIR genes and haplotypes on acute and chronic GVHD (cGVHD), transplant-related mortality (TRM), relapse and OS of 124 adult patients with hematological diseases transplanted at our center. Patients' and donors' characteristics are shown in Table 1 . Disease groups analyzed in statistical models were 'myeloid' with AML (n ¼ 37) and CML (n ¼ 35), 'lymphoid' with ALL (n ¼ 19), non-Hodgkin's lymphoma (NHL; n ¼ 11), Hodgkin's lymphoma (n ¼ 1) and CLL (n ¼ 1), and 'other' with myelodysplastic syndrome (n ¼ 14), severe aplastic anemia (n ¼ 1), multiple myeloma (n ¼ 2) and myeloproliferative disorders (n ¼ 3). The disease status was either 'standard risk', comprising CML in the first chronic phase, acute leukemias and NHL in CR or 'high risk' containing all other disease stages. In vivo T-cell depletion (TCD) was performed by anti-thymocyte globulin (Fresenius, Bad Hamburg, Germany) administration in 24% of patients. The source and numbers of transplanted stem cells, types of post transplant immunosuppressive therapy and conditioning therapies used are also shown in Table 1 . GVHD was defined as acute if occurring within the first 79 days, and as chronic if occurring at a later time point. Due to three missing onset dates, 121 patients were evaluated for aGVHD. As 22 patients died before day 79, 102 patients were evaluated for cGVHD. TRM was defined as death due to causes other than relapse. Criteria for clinical diagnoses of acute and cGVHD were previously described. 17, 18 HLA and KIR genotyping Blood samples for tissue typing were obtained upon written consent from patients and donors, and approved by the ethical committee of the Medical University of Vienna. DNA was isolated either by the salting-out method or by using an automated DNA extraction device (GenoM-6; GenoVision VertriebsgesmbH, Vienna, Austria). HLA class I and class II genes were typed to the high-resolution level by sequencing based typing. 19 Sequence specific KIR primers (SSP-KIR) and amplification conditions used for typing of KIR genes 2DL4, 3DL1, 3DL2, 3DL3, 2DL3, 2DS1, 2DS4a, 1D, 2DS5, 3DS1, 2DP1 and 3DP1 were published by Hsu et al., 3 for genes 2DL2, 2DL5, 2DS2, 2DS3, 2DS4 by Uhrberg et al. 
Patients, materials and methods

Study population
Genotype and haplotype analysis
We have compiled a list of over 100 previously published genotypes. [2] [3] [4] [5] 20 KIR genotype assignment of individuals, 3 were used to identify haplotype pairs for each of our patients and donors. Due to the lack of pseudogene variant typing and/or incomplete lists of haplotypes, ambiguities were not resolved for 19 individuals. However, broader assignment of either A (1-2) or B (3-23) haplotypes was possible in each case. The associations of KIR haplotypes with transplantation outcome were analyzed by distinguishing between AA or BX haplotypes, where X stands for either A or B haplotype. Similarly, in the genotype HLA-C1CX, CX stands for either C1 or C2 allelic groups.
Study design
To assess the effect of KIR and KIR ligands on transplantation endpoints, four models (listed in Table 2 ) were independently tested:
(1) Association of KIR ligands of patients with transplantation endpoints, regardless of donors' KIR type. 
Statistical analysis
All patient and donor characteristics, and genetic variables (patient and donor KIR genes and haplotypes, patient KIR ligands) were considered as potential risk factors for the occurrence of acute and cGVHD, relapse, TRM and OS. Acute and cGVHD were also considered as potential factors impacting relapse, TRM and OS. Clinical factors with P values less than 0.20 by simple log-rank tests were included in a multiple Cox-regression for model selection purposes. Then, the set of clinical variables with significant influence on the outcome in the final Cox-regression model was identified by the stepwise selection. Before these analyses, age was dichotomized using Classification and Regression Trees (CART). 21, 22 The effect of each genetic factor was assessed by simple and by multiple Coxregression models. In the latter case, the multiple model included the significant clinical factors previously obtained, plus one genetic factor, so that the effect of each genetic factor was adjusted by the effects of the significant clinical factors.
The competing risk method for survival analysis 23 was carried out to assess the single effect of the genetic factors. Relapse and TRM are competing risks for acute and cGVHD, and TRM is a competing risk for relapse and vice versa.
To address the question whether dAA/pAA HLA-C1CX contributes to the effect on aGVHD (II-IV) independently of dAA/pAA HLA-Bw4 À , the risk of aGVHD (II-IV) in the subgroup dAA/pAA, HLA-C1CX, -Bw4 þ patients was assessed.
Clinical variables are reported only if reaching significance in the final multiple models. Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated in each analysis. The significance level was set to 0.05 without adjustment for multiple testing.
Results
Overall aGVHD was diagnosed in 62 (51%) patients, including 44 (36%) patients with aGVHD (II-IV). Median time to onset of aGVHD was 16 days (range 7-52 days). Limited cGVHD was diagnosed in 9 (9%), and extensive in 27 (26%) patients. Median time to onset of cGVHD was 176 days (range 80-840 days). Of the patients, 40 (32%) experienced relapse by the end of the follow up, whereas 25 patients (20%) died of transplant related causes. By the end of the follow-up period, 67 patients (54%) were alive.
Multiple analyses of genetic and clinical variables of patients and donors revealed their association with aGVHD (II-IV). Consistent with these findings, multiple Cox regression analyses showed that HLA-C1C1 patients were at higher risk for developing aGVHD (II-IV) (HR ¼ 3.26, 95% CI: 0.97-10.91, P ¼ 0.055), this effect, however, is not reaching statistical significance (Table 2 ). In addition to KIR ligands, type of diagnosis, stage of the disease, TCD, stem cell source and age of donor were analyzed in multiple models for an association with aGVHD (II-IV). Only TCD (HR ¼ 0.26, 95% CI: 0.09-0.72, P ¼ 0.010) and donor age above 37 years (HR ¼ 0.52, 95% CI: 0.28-0.98, P ¼ 0.042) were significantly associated with less aGVHD (II-IV). TCD and donor age were also significantly associated with aGVHD outcomes in all other multiple analyses.
Association of 'missing ligands' with acute GVHD (II-IV)
In 113 of 121 patients (91%), at least one ligand was missing for the corresponding inhibitory KIR of the donor. Of the patients, 20 (17%) missed HLA-C1, 48 (40%) missed HLA-C2 and 49 (41%) missed HLA-Bw4 ligands for corresponding donors' KIRs. Further on, when the combination of two missing ligands was analyzed, 3 (2%) patients missed HLA-C1 and HLA-Bw4 ligands, and 31 (26%) patients missed both HLA-C2 and HLA-Bw4 combinations.
In simple Cox analyses, missing HLA-C2 ligands for donors' KIR2DL1 (HR ¼ 2.80, 95% CI: 1.53, 5.10, P ¼ 0.0008) and missing HLA-Bw4 ligands for donors' KIR3DL1 (HR ¼ 1.99, 95% CI: 1.10-3.60, P ¼ 0.023) were significantly associated with a higher incidence of aGVHD (II-IV). Competing risk analyses, however, confirmed only the significant association of missing ligands for donors' KIR2DL1 with aGVHD (II-IV) (HR ¼ 3.00, 95% CI: 1.83-4.93, P ¼ 0.00001).
In multiple Cox regression analyses, only the absence of ligands for donors' KIR2DL1 was a significant risk factor for occurrence of aGVHD (II-IV) (HR ¼ 2.23, CI: 1.21-4.10, P ¼ 0.010; Figure 1a ; Table 2 ). When the association of two or more missing ligands with the aGVHD (II-IV) was analyzed in simple or multiple models, an additive effect was not observed and hazard ratios did not significantly change (data not shown).
Association of donors' activatory KIR genes with acute GVHD (II-IV)
The frequencies of activatory KIR genes in our donor and patient populations were similar, and comparable to those of other European populations (www.allelefrequencies.net). Of the donors, 42 (35%) were positive for KIR2DS1, 52% for KIR2DS2, 28% for KIR2DS3, 89% for KIR2DS4, 29% for KIR2DS5 and 38% for KIR3DS1.
Simple Cox analysis showed a significant association of donors' KIR2DS2 with aGVHD (II-IV) (HR ¼ 0.54, 95% CI: 0.29-0.99, P ¼ 0.047). When taking into account patients' KIR ligands in the simple analyses, we observed that the presence of donor's KIR2DS2 in HLA-C1C2 patients (HR ¼ 0.21, 95% CI: 0.06-0.75, P ¼ 0.016) was associated with a reduced risk of aGVHD (II-IV). Competing risk analysis of the same parameters showed a similar result (HR ¼ 0.24, 95% CI: 0.09-0.63 P ¼ 0.003).
After the clinical covariables were included in the multiple analyses, the presence of KIR2DS2 gene was associated with a reduced incidence of aGVHD (II-IV) in HLA-C1C2 patients (HR ¼ 0.24, 95% CI: 0.07-0.85, P ¼ 0.027; Figure 1b , Table 2 ).
Association of KIR haplotypes with acute GVHD (II-IV)
Of 121 patients, 38 (32%) and 39% of donors (47 of 121) had the AA KIR haplotypes whereas the rest of our population had AB or BB haplotypes (BX haplotypes). The distribution of haplotypes is therefore comparable with those reported elsewhere. 4, 15 We first analyzed the association of patient/donor haplotype combinations-dBX/pAA (n ¼ 21, 17%), dBX/ pBX (n ¼ 53, 44%), dAA/pAA (n ¼ 17, 14%) and dAA/ pBX (n ¼ 31, 25%)-with transplantation endpoints. None of the patient and donor haplotype combinations was significantly associated with transplantation endpoints in simple or in competing risk analyses. Nevertheless, after adjustment by clinical covariables, the group of patients with KIR AA haplotypes receiving grafts from donors with KIR AA haplotypes was at higher risk of aGVHD (II-IV) (HR ¼ 2.18, 95% CI: 1.00-4.75, P ¼ 0.050), with borderline significance (Table 2) .
In simple Cox analyses, KIR haplotypes were analyzed together with HLA-C2C2, -C1CX, -Bw4 þ and -Bw4 À types of patients; the combinations dAA/pAA and HLA-C1CX (HR ¼ 2.13, 95% CI: 1.05-4.31, P ¼ 0.036) and dAA/pAA and HLA-Bw4 À (HR ¼ 3.50, 95% CI: 1.48-8.32, P ¼ 0.005) were significantly associated with an increased risk of Adjustment by the clinical variables in Cox-regression models showed that only KIR AA haplotypes in patients and donors were associated with an increased risk of aGVHD (II-IV) in HLA-C1CX (HR ¼ 2.37, 95% CI: 1.16-4.84, P ¼ 0.018) and in HLA-Bw4 À (HR ¼ 3.20, 95% CI: 1.35-7.60, P ¼ 0.008), but not in HLA-C2C2 or -Bw4 þ patients ( Figure 1c and Table 2 ).
Other KIR/HLA haplotype combinations analyzed in the multiple models were not significantly associated with aGVHD (II-IV).
Considering that all 7 dAA/pAA, HLA-Bw4 À patients are included in the group of 17 dAA/pAA, HLA-C1CX patients, we further explored whether the association of dAA/pAA, HLA-C1CX with aGVHD (II-IV) is influenced by the group of dAA/pAA, HLA-Bw4 À patients. The analyses of dAA/pAA, HLA-C1CX (HLA-Bw4 þ ) haplotypes did not show evidence of an association with increased aGVHD (II-IV) (HR ¼ 1.96, 95% CI: 0.62-6.12, P ¼ 0.250), indicating that the significant effect initially found for dAA/pAA, HLA-C1CX was influenced by HLA-Bw4
Chronic GVHD, relapse, transplant-related mortality and overall survival In any of the four models of KIR gene/KIR ligand interaction analyzed we did not find significant associations with cGVHD, relapse, TRM or OS in simple or multiple analyses.
Discussion
This study provides evidence of an association of KIR genes and KIR ligands with aGVHD (II-IV), but not with other endpoints of HSCT, in 124 patients receiving 12/12 HLA matched unrelated donors grafts.
Our analyses revealed that HLA-C1C1 tends to be a risk factor for aGVHD (II-IV). If HLA-C1C1 patients received grafts from KIR2DL1 negative donors, this effect was highly significant. Importantly, the association with the aGVHD cannot be attributed to HLA mismatches, as all patient/donor pairs in our study were matched at 12/12 HLA loci. HLA-DPB1 typing, in addition, showed that this increase of aGVHD (II-IV) is independent of the HLA-DPB1 matching (data not shown).
Our findings are in line with the results of two recent studies analyzing the outcome of HLA matched sibling HSCT. McQueen et al. 15 observed a trend toward a higher incidence of aGVHD in HLA-C1C1 patients receiving non-TCD grafts, and Verheyden et al. 24 observed a significantly higher incidence of aGVHD in HLA-C1C1 and ÀC2C2 transplant patients.
By contrast, other investigators reported either no effect of KIR ligands on aGVHD in AML patients, 25 or decreased aGVHD (III-IV) in HLA-C1C1 CML patients. 13 When the analyses were performed according to the 'missing ligand' concept, Miller et al. 26 reported that, similar to our findings, early CML patients were at higher risk of aGVHD (III-IV). Other reports, however, showed no association of missing ligands with aGVHD after HLA identical sibling transplantation, neither with unmanipulated 27, 28 nor with TCD grafts. 10 When analyzing activatory genes only donors' KIR2DS2 was associated with lower risk for aGVHD (II-IV), and after including KIR ligands in multiple models, the same association remained only in HLA-C1C2 patients. This is, to our knowledge, the first observation of a protective effect of the KIR2DS2 on aGVHD (II-IV). Regarding the role of activatory KIR genes in transplantation, Gagne et al. 29 have reported that KIR2DS3 in donors is a potential high risk marker for aGVHD. Also, donor's KIR2DS2 was shown to be associated with worse OS in HLA-C2C2 patients with myeloid leukemia.
14 Although the ligands for activatory receptors are not known, our finding concerning KIR2DS2 indicates there might be different molecular pathways of activation of individual activatory KIR genes.
The analyses of KIR haplotypes showed pAA/dAA to be significantly associated with increased aGVHD (II-IV), and after including KIR ligands in multiple analyses this association was significant only in HLA-C1 þ and in HLABw4 À patients. Haplotypes A lack most of the activatory genes and, similarly, NK cells of HLA-C1C1 and HLABw4 À patients have a low activatory potential due to the weak inhibitory signals during their development. 30 Therefore, there might be a link between those NK cells and increased T-cell alloreactivity, but its exact nature still has to be elucidated.
Although our results and recent findings of Cooley et al., 2008 31 point to a negative effect of AA donor haplotypes regarding aGVHD and OS in unrelated donor HSCT, McQueen et al. 15 find B haplotypes predictive of aGVHD in sibling HSCT. Thus, the effect of the KIR haplotypes might depend on differences in clinical protocols used for sibling vs transplantations with unrelated donors.
The role of NK cells in the pathophysiology of aGVHD remains to be elucidated. aGVHD is a T-cell-mediated disease, but there is evidence showing that it can be modified by IFN-g production of NK cells and by the kinetics of KIR receptor reconstitution. 32 It might be possible that NK cells, activated through missing ligand mechanisms, create a setting in which T cells cause aGVHD. Sun et al. 33 suggested that the combined alloreactivity of T and NK cells in the graft might 'bring the alloimmune response beyond appropriate level and cause inferior transplantation outcome'. In addition to this indirect effect, alloreactive NK cells might directly attack non-hematopoietic cells and so contribute to aGVHD. This hypothesis is in line with recent findings that NK cells are able to adhere to endothelial cells, which suggest they play a role in vascular injuries or solid organ failures (reviewed by Vivier et al.
34
). Besides, the possibility cannot be excluded that the observed association of donor KIR receptors with increased aGVHD might be due to the alloreactive KIR expressing T cells, as the signaling through NK receptors on T cells was shown to affect TCR mediated functions in B-CLL and other target cells. [35] [36] [37] [38] The discrepancies between studies regarding the effects of KIR ligands, 'missing ligands', and KIR haplotypes on HSCT outcome could be due to the variable degrees of HLA matching. Not less important are substantial differences in underlying disease and transplant protocols including conditioning regiments, composition of allograft and GVHD prophylaxis.
The stringent setup of our single center study, based on the patient/donor 12/12 HLA match and KIR gene assessment, showed a significant association of KIR/HLA genes and haplotypes with increased risk of aGVHD (II-IV), but not other transplant endpoints. Further studies will be necessary to understand the role of KIR genes in the pathophysiology of aGVHD under distinct clinical conditions. The prognostic value of our results should be validated in a larger study.
